In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin

Bibliographic Data

ID15527201
AuthorsN Jones (0000-0002-1762-6590, University of Wisconsin–Madison), Nathan T Jones, Laura Wagner (0000-0001-8557-4844), Laura M Wagner (0000-0002-9629-2153, University of Wisconsin–Madison), Molly C Pellitteri Hahn (University of Wisconsin–Madison), Cameron O Scarlett (0009-0004-5902-4637, University of Wisconsin–Madison), Cody J Wenthur (0000-0001-6043-3842, University of Wisconsin–Madison, corresponding author)
Year2024
Volume14
Pages1303365-1303365
Publication date2024-01-08
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueFrontiers in Psychiatry (JOURNAL)
Journal identifiersISSN: 1664-0640 • E-ISSN: 1664-0640
PublisherFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2023.1303365
PMID38264637
OpenAlexW4390665254
LanguageEN
References cited40

These findings provide the first direct support for the long-standing assumption in the field that psilacetin functions as a prodrug for psilocin in vivo . In addition, these results indicate that psilacetin fumarate results in lower peripheral psilocin exposure than psilocybin when dosed on an equimolar basis. Thoughtful substitution of psilocybin with psilacetin fumarate appears to be a viable approach for conducting mechanistic psychedelic research in C57Bl6/J mice

Active metabolite · Biology · Hallucinogen · In vivo · Metabolite · Prodrug · Psilocybin · Chemical synthesis and alkaloids · Chemistry · Medicine · Neurotransmitter Receptor Influence on Behavior · Psychedelics and Drug Studies · Biochemistry · Pharmacology

Tools

Open DOIOpen Access